Medicare Enrolled
Dr. Mohammad Kazmi, M.D.
Optician · Lodi, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kazmi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kazmi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kazmi
Dr. Mohammad Kazmi is an optician specialist in Lodi, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Kazmi performed 1,334 Medicare services across 896 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kazmi received a total of $21,507 from 84 pharmaceutical and/or device companies across 1214 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kazmi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 47% volume in CA
$21,507 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,334
Medicare services
Top 47% in CA for optician
896
Unique beneficiaries
$98
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~67 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
794 | $99 | $280 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
191 | $130 | $360 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
91 | $64 | $147 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
87 | $139 | $408 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
55 | $31 | $198 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
37 | $95 | $211 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
29 | $46 | $195 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
20 | $106 | $278 |
| EEG, extended monitoring A test that records electrical activity in the brain while the patient is both awake and asleep. |
19 | $45 | $150 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
11 | $60 | $279 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$21,507
Total received (2018-2024)
Avg $3,072/year across 7 years
Top 8% in CA for optician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
84
Companies
1,214
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$21,303 (99.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$204 (1.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,286
2023
$3,284
2022
$4,644
2021
$2,691
2020
$1,818
2019
$2,701
2018
$2,082
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
MDD US Operations, LLC
$479
ABBVIE INC.
$408
UCB, Inc.
$377
SK Life Science, Inc.
$247
Alexion Pharmaceuticals, Inc.
$238
Biogen, Inc.
$222
Neurocrine Biosciences, Inc.
$211
Amgen Inc.
$162
Otsuka America Pharmaceutical, Inc.
$161
PFIZER INC.
$157
ARGENX US, INC.
$152
Eisai Inc.
$117
ACADIA Pharmaceuticals Inc
$107
LivaNova USA, Inc.
$102
Aucta Pharmaceuticals, Inc.
$94
Takeda Pharmaceuticals U.S.A., Inc.
$93
Lilly USA, LLC
$90
Vanda Pharmaceuticals Inc.
$85
Celgene Corporation
$76
Neurelis, Inc.
$71
GE HEALTHCARE
$66
Amneal Pharmaceuticals LLC
$58
MITSUBISHI TANABE PHARMA AMERICA, INC.
$51
Medtronic, Inc.
$45
Merz Pharmaceuticals, LLC
$45
Novartis Pharmaceuticals Corporation
$44
Kyowa Kirin, Inc.
$44
Genentech USA, Inc.
$37
EMD Serono, Inc.
$34
BANNER LIFE SCIENCES, LLC
$32
Averitas Pharma Inc.
$29
Lundbeck LLC
$28
Boehringer Ingelheim Pharmaceuticals, Inc.
$27
JAZZ PHARMACEUTICALS INC.
$23
Octapharma USA, Inc.
$21
Kedrion Biopharma, Inc.
$19
NEUROPACE, INC.
$19
CSL Behring
$16
Top 3 companies account for 29.5% of 2024 payments
All-time payments by company (2018-2024) ›
UCB, Inc.
$1,690
ABBVIE INC.
$1,594
Biogen, Inc.
$1,198
GENZYME CORPORATION
$993
SK Life Science, Inc.
$768
ACADIA Pharmaceuticals Inc
$727
Lilly USA, LLC
$718
Alexion Pharmaceuticals, Inc.
$664
Neurocrine Biosciences, Inc.
$654
Amgen Inc.
$623
Amneal Pharmaceuticals LLC
$591
EMD Serono, Inc.
$576
Novartis Pharmaceuticals Corporation
$503
Teva Pharmaceuticals USA, Inc.
$499
MDD US Operations, LLC
$479
Medtronic USA, Inc.
$460
Allergan, Inc.
$381
PFIZER INC.
$375
Eisai Inc.
$374
IMPEL PHARMACEUTICALS INC.
$357
ARGENX US, INC.
$329
Biohaven Pharmaceutical Holding Company Ltd.
$327
LivaNova USA, Inc.
$327
Sunovion Pharmaceuticals Inc.
$297
Allergan Inc.
$285
Janssen Pharmaceuticals, Inc
$283
Supernus Pharmaceuticals, Inc.
$276
SANOFI-AVENTIS U.S. LLC
$264
Genentech USA, Inc.
$250
Acorda Therapeutics, Inc
$249
Otsuka America Pharmaceutical, Inc.
$231
Lundbeck LLC
$225
Boehringer Ingelheim Pharmaceuticals, Inc.
$220
Neurelis, Inc.
$217
AbbVie Inc.
$191
US WorldMeds, LLC
$187
Celgene Corporation
$177
Avanir Pharmaceuticals, Inc.
$174
Abbott Laboratories
$174
Adamas Pharmaceuticals, Inc.
$159
Biohaven Pharmaceuticals, Inc.
$150
Merz Pharmaceuticals, LLC
$139
Takeda Pharmaceuticals U.S.A., Inc.
$139
Horizon Therapeutics plc
$136
Novo Nordisk Inc
$128
Catalyst Pharmaceuticals, Inc.
$105
Grifols USA, LLC
$105
Greenwich Biosciences, Inc.
$97
Aucta Pharmaceuticals, Inc.
$94
EISAI INC.
$85
Vanda Pharmaceuticals Inc.
$85
Kyowa Kirin, Inc.
$80
CSL Behring
$75
Medtronic, Inc.
$70
GE HEALTHCARE
$66
Shire North American Group Inc
$66
MITSUBISHI TANABE PHARMA AMERICA, INC.
$51
BANNER LIFE SCIENCES, LLC
$50
PORTOLA PHARMACEUTICALS, INC.
$49
Akcea Therapeutics, Inc.
$45
JAZZ PHARMACEUTICALS INC.
$45
MannKind Corporation
$42
Banner Life Sciences, LLC
$41
Octapharma USA, Inc.
$40
Impax Laboratories, Inc.
$38
E.R. Squibb & Sons, L.L.C.
$35
Averitas Pharma Inc.
$29
Sumitomo Pharma America, Inc.
$28
IDORSIA PHARMACEUTICALS US INC
$27
Becton, Dickinson and Company
$27
BIOTISSUE HOLDINGS, INC.
$25
Exeltis, USA Inc.
$25
Bayer HealthCare Pharmaceuticals Inc.
$24
BioTissue Holdings, Inc.
$23
GE HealthCare
$23
Cala Health, Inc.
$21
Ceribell, Inc.
$19
Kedrion Biopharma, Inc.
$19
Silk Road Medical, Inc.
$19
NEUROPACE, INC.
$19
DEXCOM, INC.
$16
Merz North America, Inc.
$16
CeQur Corporation
$14
Boston Scientific Corporation
$13
Top 3 companies account for 20.8% of all-time payments
Associated products mentioned in payments ›
ACTIVA · ADUHELM · AFINITOR · AFREZZA · AIMOVIG · AJOVY · AMPYRA · AMYVID · ANDEXXA · APOKYN · APTIOM · AUBAGIO · AUSTEDO · AVONEX · Aimovig · Albuked · Austedo XR · BAFIERTAM · BAQSIMI · BD Nano · BOTOX · BOTOX THERAPEUTIC · Briviact · CALA KIQ · COMIRNATY · COPAXONE · CeQur Simplicity · Cenobamate · Crysvita · DEXCOM G6 TRANSMITTER · DIABETES - DISEASE · DUOPA · Dayvigo · EMGALITY · ENROUTE Transcarotid Neuroprotection System · EPIDIOLEX · Enspryng · Epidiolex · FIRDAPSE · FYCOMPA · Fintepla · FreeStyle Libre · Fycompa · GENERAL DBS · GILENYA · GOCOVRI · Gamunex-C · Gocovri · HETLIOZ · HYQVIA · Hizentra · INBRIJA · INGREZZA · Infinity DBS Pulse Generators · JARDIANCE · KESIMPTA · KISUNLA · KYNMOBI · Kerendia · LANTUS · LEMTRADA · LEQEMBI · LONHALA MAGNAIR · Leqembi · MAVENCLAD · MAYZENT · MINIMED 770G · MINIMED 780G · MYOBLOC · Mavenclad · Motpoly XR · NAMZARIC · NATPARA · NATPARA (PARATHYROID HORMONE) · NEOX · NORTHERA · NOURIANZ · NUEDEXTA · NUPLAZID · NURTEC ODT · Nayzilam · Neupro · Nourianz · Nuedexta · OCREVUS · ONGENTYS · OXTELLAR XR · Ocrevus · Ongentys · Ozempic · PANZYGA · PAXLOVID · PONVORY · PURIFIED CORTROPHIN GEL · Ponvory · QULIPTA · QUTENZA · QUVIVIQ · RADICAVA · REXULTI · REYVOW · RNS Neurostimulator Kit · RYBELSUS · RYTARY · Rebif · Rystiggo · SOLIQUA 100/33 · SOLIRIS · STRENSIQ · SYNTHROID · Soliris · TECFIDERA · TEGSEDI · TEPEZZA · TOUJEO · TROKENDI XR · TYSABRI · Trintellix · Trudhesa · UBRELVY · ULTOMIRIS · UPLIZNA · Utibron · VALTOCO · VNS - Sentiva · VNS THERAPY SENTIVA MODEL 1000 GENERATOR · VNS Therapy · VRAYLAR · VUMERITY · VYEPTI · VYVGART · VYVGART HYTRULO · Vimpat · XARELTO · XCOPRI · XEOMIN · Xadago · Xembify · Xeomin · ZAVZPRET · ZEPOSIA · Zilbrysq
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 8% for optician in CA.
Geographic Context
Opticians within 10 mi
71
Per 100K population
9.0
County median income
$88,531
Nearest hospital
ADVENTIST HEALTH LODI MEMORIAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kazmi is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement in the top 8% of CA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kazmi experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Kazmi performed 794 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kazmi receive payments from pharmaceutical companies?
Yes. Dr. Kazmi received a total of $21,507 from 84 companies across 1,214 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kazmi's costs compare to other opticians in Lodi?
Dr. Kazmi's average Medicare payment per service is $98. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kazmi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Lodi
Browse opticians in Lodi ranked by procedure volume and transparency data.
Highest volume
Top Opticians in CA
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in CA
Which CA opticians receive the most from drug and device companies.
By company
UCB, Inc. Payments to Doctors
See all physicians who received payments from UCB, Inc.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
By company
Biogen, Inc. Payments to Doctors
See all physicians who received payments from Biogen, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology